PMID- 2849981
OWN - NLM
STAT- MEDLINE
DCOM- 19890213
LR  - 20190704
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 70
IP  - 3
DP  - 1988 Nov
TI  - Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and 
      in vivo anticoagulant effect of very low molecular weight heparin, CY222.
PG  - 335-40
AB  - There is uncertainty as to which activities of unfractionated heparin (UFH) and 
      low MW heparin are responsible for their anticoagulant and antithrombotic 
      properties. We have sought to answer this question by examining plasma samples 
      taken during a recently conducted dose-finding study of the low MW heparin, 
      CY222, in haemodialysis for chronic renal failure. In this study, in vivo 
      anticoagulant effect was assessed by measurement of plasma FPA levels. UFH was 
      administered as a dose of 5000 iu bolus + 1,500 iu/h maintenance infusion, while 
      the effects of three doses of CY222 were studied (10,000, 15,000 and 20,000 
      Institute Choay anti-factor Xa u bolus, all with 1,500 Institute Choay 
      anti-factor Xa u/h maintenance infusion). Anti-factor Xa levels were determined 
      by chromogenic substrate assay. Anti-thrombin levels were determined by 
      chromogenic substrate assay and by quantitation of catalysed thrombin-inhibitor 
      complexes (using autoradiography). Analysis of the results indicate that plasma 
      fibrinopeptide A (FPA) levels correlate with anti-factor Xa (r = -0.45) and 
      anti-thrombin (substrate) (r = -0.63) levels of UFH, but only with the 
      anti-factor Xa levels (r = -0.41) of CY222. These results suggest that the 
      anti-factor Xa assay is currently the most suitable assay for monitoring low MW 
      heparins such as CY222 in humans.
FAU - Tew, C J
AU  - Tew CJ
AD  - Department of Haematology, Charing Cross and Westminster Hospital and Medical 
      School, London.
FAU - Lane, D A
AU  - Lane DA
FAU - Thompson, E
AU  - Thompson E
FAU - Ireland, H
AU  - Ireland H
FAU - Curtis, J R
AU  - Curtis JR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Anticoagulants)
RN  - 0 (Dipeptides)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Serine Proteinase Inhibitors)
RN  - 25422-31-5 (Fibrinopeptide A)
RN  - 64815-81-2 (S 2238)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Anticoagulants/*pharmacology
MH  - Dipeptides
MH  - Factor Xa
MH  - Fibrinopeptide A/analysis
MH  - Heparin/pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Humans
MH  - Protease Inhibitors/*blood
MH  - *Serine Proteinase Inhibitors
MH  - Thrombin/*antagonists & inhibitors
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1111/j.1365-2141.1988.tb02491.x [doi]
PST - ppublish
SO  - Br J Haematol. 1988 Nov;70(3):335-40. doi: 10.1111/j.1365-2141.1988.tb02491.x.